11C-Choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large U.S. Patient Series

Conclusion: 11C-choline PET/CT can detect PCa recurrence even among patients with low PSA levels when interpretation accounts for the clinical context, providing a certain pretest probability. Until prostate-specific membrane antigen agents are fully approved for PCa, choline PET/CT may provide clinical utility.

Source: Journal of Nuclear Medicine - June 3, 2020 Category: Nuclear Medicine Authors: Michaud, L., Touijer, K. A., Mauguen, A., Zelefsky, M. J., Morris, M. J., Lyashschenko, S. K., Durack, J. C., Humm, J. L., Weber, W. A., Schoder, H. Tags: Clinical Source Type: research